Metabolic Syndrome Scientific Statement by the American Heart Association and the National Heart, Lung, and Blood Institute

HomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 25, No. 11Metabolic Syndrome Scientific Statement by the American Heart Association and the National Heart, Lung, and Blood Institute Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBMetabolic Syndrome Scientific Statement by the American Heart Association and the National Heart, Lung, and Blood Institute Scott M. Grundy Scott M. GrundyScott M. Grundy From the Center for Human Nutrition, Departments of Clinical Nutrition and Internal Medicine, University of Texas, Southwestern Medical Center at Dallas. Originally published1 Nov 2005https://doi.org/10.1161/01.ATV.0000189155.75833.c7Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2243–2244The metabolic syndrome is a constellation of risk factors that are associated with increased risk for atherosclerotic cardiovascular disease (ASCVD), type 2 diabetes, and their complications. This constellation consists of 5 metabolic risk factors that together increase the risk for ASCVD. These include atherogenic dyslipidemia, elevated blood pressure, elevated glucose, a prothrombotic state, and a proinflammatory state. Atherogenic dyslipidemia consists of elevations of serum total apolipoprotein B (apoB), triglycerides, small particles in low density lipoprotein (LDL), and low levels of high density lipoproteins (HDL). An elevated glucose can be in the range of impaired fasting glucose (IFG), which is called prediabetes, or at the level of diabetes. Available evidence suggests that all of the metabolic risk factors are independently atherogenic. Moreover, individuals with metabolic syndrome, particularly when IFG is present, have a high likelihood of progression to type 2 diabetes.See Circulation. 2005;112:e285The metabolic syndrome has a multifactorial causation. The predominant underlying risk factors are obesity (especially abdominal obesity) and insulin resistance. These often occur together, and their relative contributions to the syndrome have not been fully defined. Nonetheless, there is a general agreement that the increasing prevalence of obesity in the United States and worldwide is mainly responsible for the increasing occurrence of the syndrome. Other factors that can exacerbate the metabolic syndrome are physical inactivity, advancing age, endocrine dysfunction, and genetic susceptibility.In 2001, the National Cholesterol Education Program Adult Treatment Panel III (ATP III)1,2 proposed that the metabolic syndrome be introduced into clinical practice as a risk companion to elevated LDL cholesterol (LDL-C). The concept of the syndrome presented in ATP III was based on more than 2 decades of research on the clustering of metabolic risk factors. The syndrome was viewed as a clinical condition that is largely elicited by obesity and as one that deserves clinical intervention in practice. The rising prevalence of obesity in the United States was a major stimulus for including the metabolic syndrome as a component of the cholesterol guidelines. For routine practice, simple clinical criteria were proposed for a clinical diagnosis of the syndrome. Diagnosis was based on the identification of at least 3 of 5 risk factors: increased waist circumference (abdominal obesity), increased serum triglyceride, reduced HDL cholesterol (HDL-C), elevated blood pressure, and elevated glucose.After publication of the ATP III, questions were raised in the cardiovascular and diabetes communities as to whether the diagnostic criteria are reliable and whether clinical intervention to reduce risk for ASCVD and diabetes is warranted. In response, the National Heart, Lung, and Blood Institute (NHLBI) cosponsored a workshop on clinical definition with the American Heart Association (AHA). This was followed by a workshop on clinical management of the metabolic syndrome sponsored by the AHA, NHLBI, and American Diabetes Association (ADA). Summaries of these workshops were published in 2004.3,4 Thereafter the AHA and NHLBI organized a writing group to incorporate the findings of these workshops and to review the emerging information on metabolic syndrome for the purpose of issuing a scientific statement to update the ATP III report.The AHA/NHLBI update of ATP III metabolic syndrome has recently been published in Circulation.5,6 The executive summary and the full report of this update are available on-line on the Circulation website, on the AHA website under scientific statements, and on the NHLBI website. The full report will be published in print in Circulation. The clinical criteria for diagnosis of metabolic syndrome proposed in the ATP III update are shown in the Table. These criteria represent only minor modifications of the original ATP III report.1,2 Waist circumference thresholds are the same except that it is noted that lower thresholds are appropriate for persons who have clinical evidence of insulin resistance or who are members of ethnic groups in which the prevalence of insulin resistance is high. No changes were made in cutpoints for triglycerides or HDL-C; but when individuals are on lipid-lowering drugs for these risk factors they can be considered to have these risk factors. An elevated blood pressure is defined as a systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥85 mm Hg or on drug treatment for hypertension. The threshold for increased fasting glucose was reduced from 110 mg/dL to 100 mg/dL in accord with the recent change in the ADA definition of impaired fasting glucose.7Diagnostic Criteria for Metabolic SyndromeMeasure (any 3 of the 5 criteria below constitute a diagnosis of metabolic syndrome)Categorical Cutpoints*To measure waist circumference, locate top of right iliac crest. Place a measuring tape in a horizontal plane around abdomen at level of iliac crest. Before reading tape measure, ensure that tape is snug but does not compress the skin and is parallel to floor. Measurement is made at the end of a normal expiration.†In the United States, some adults of non-Asian origin (eg, White, Black, Hispanic) with a marginally increased waist circumference (eg, 94–101 cm [37–39 in] in men and 80–87 cm [31–34 in] in women) may have a strong genetic contribution to insulin resistance; they should benefit from changes in life habits, similarly to men with categorical increases in waist circumference. A lower waist circumference cut point (eg, ≥90 cm [35 in] in men and ≥80cm [31 in] in women) appears to be appropriate for persons of Asian origin.‡The most commonly used drugs for elevated TG and reduced HDL-C are fibrates and nicotinic acid. A patient on one of these drugs can be presumed to have high TG and low HDL.Elevated waist circumference*†≥102 cm (>40 inches) in males≥88 cm (>35 inches) in femalesElevated triglycerides≥150 mg/dL (1.7 mmol/L) orOn drug treatment for elevated triglyceride‡Reduced HDL cholesterol<40 mg/dL (0.9 mmol/L) in males<50 mg/dL (1.1 mmol/L) in females orOn drug treatment for reduced HDL-C‡Elevated blood pressure≥130 mm Hg systolic blood pressure or≥85 mm Hg diastolic blood pressure orOn drug treatment for hypertension is an alternate indicatorElevated fasting glucose≥100 mg/dL orOn drug treatment for elevated glucoseRecently the International Diabetes Federation (IDF) proposed similar criteria for the metabolic syndrome.8 IDF requires that evidence of abdominal obesity be present for a clinical diagnosis of the syndrome. Criteria for abdominal obesity are ethnic-specific. Otherwise, 3 of 5 risk factors, one of which must be abdominal obesity, are needed for diagnosis. The risk factors are identical to those of ATP III, as are the thresholds to define abnormality.The ATP III update placed primary emphasis on lifestyle therapies for clinical management of metabolic syndrome. These include weight reduction, increased physical activity, and an antiatherogenic diet. Drug therapies for categorical risk factors depend on established guidelines from the AHA, NHLBI, and ADA for treatment of obesity, physical inactivity, lipid disorders, hypertension, a prothrombotic state, and diabetes. The metabolic syndrome is not a risk assessment tool for determining absolute risk to guide clinical management of individual risk factors with drug therapies. Established risk-assessment algorithms should be utilized for this purpose.1,2 But recognition of the syndrome in clinical practice is encouraged for the identification of a multiple-risk-factor condition and to promote lifestyle therapies that will reduce all of the metabolic risk factors simultaneously. Appropriate management of the metabolic syndrome offers an opportunity to reduce risk for both ASCVD and type 2 diabetes beyond what can be achieved by therapies directed toward single risk factors.The AHA/NHLBI update,5,6 the IDF report,8 and a recent article from the ADA9 all point out that more research is needed to better understand the pathogenesis of the metabolic syndrome. It is expected that all of these reports will engender increased interest in the syndrome and will promote research. Because of the complexity of the syndrome, there are many potential areas for research that will enhance our understanding of the metabolism of carbohydrates, fats, proteins, and their regulation and pathogenesis of the syndrome.FootnotesCorrespondence to Scott M. Grundy, MD, PhD, Center for Human Nutrition, Departments of Clinical Nutrition and Internal Medicine, University of Texas, Southwestern Medical Center at Dallas, 323 Harry Hines Blvd, Y3.206, Dallas, TX 75390-9052. E-mail [email protected] References 1 Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc. 2001; 285: 2486–2497.CrossrefMedlineGoogle Scholar2 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143–3421.LinkGoogle Scholar3 Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004; 109: 433–438.LinkGoogle Scholar4 Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA; American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004; 109: 551–556.LinkGoogle Scholar5 Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr., Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112: 2735–2752.LinkGoogle Scholar6 Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr., Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive Summary. Circulation. 2005; 112: e285–e290.LinkGoogle Scholar7 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26: 3160–3167.CrossrefMedlineGoogle Scholar8 Alberti KG, Zimmet P, Shaw J;d for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome–a new worldwide definition. Lancet. 2005; 366: 1059–1062.CrossrefMedlineGoogle Scholar9 Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the Am Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005; 28: 2289–2304.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Suire K, Peart A, Kavookjian J and Wadsworth D (2022) Impact of motivational interviewing as a follow-up to an exercise intervention among women with or at risk for metabolic syndrome: A randomized controlled trial, SAGE Open Medicine, 10.1177/20503121211073434, 10, (205031212110734), Online publication date: 1-Jan-2022. Chen H, Zheng X, Zong X, Li Z, Li N, Hur J, Fritz C, Chapman Jr W, Nickel K, Tipping A, Colditz G, Giovannucci E, Olsen M, Fields R and Cao Y (2020) Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer, Gut, 10.1136/gutjnl-2020-321661, 70:6, (1147-1154), Online publication date: 1-Jun-2021. Betts A, Ochoa C, Hamilton R, Sikka S and Froehlich-Grobe K (2021) Barriers and Facilitators to Lifestyle Intervention Engagement and Weight Loss in People Living With Spinal Cord Injury, Topics in Spinal Cord Injury Rehabilitation, 10.46292/sci20-00025, 27:1, (135-148), Online publication date: 1-Jan-2021. Sommer I, Gangadin S, de Witte L, Koops S, van Baal C, Bahn S, Drexhage H, van Haren N, Veling W, Bruggeman R, Martens P, Wiersma S, Veerman S, Grootens K, van Beveren N, Kahn R and Begemann M (2021) Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial, Schizophrenia Bulletin, 10.1093/schbul/sbab010, 47:4, (1108-1115), Online publication date: 8-Jul-2021. Lee M, Suh Y, Hong S and Kim D (2021) Waist-to-Height Ratio as an Index for Screening Lifestyle-Related Diseases in Overweight Adults, Keimyung Medical Journal, 10.46308/kmj.2021.00101, 40:1, (32-38), Online publication date: 15-Jun-2021. Rafati S, Isheh M, Azarbad A, Ghadiri Soufi F, Rahimi A and Kheirandish M (2021) The association of sleep duration and metabolic syndrome in the Bandare-Kong cohort study, a cross-sectional survey (finding from PERSIAN cohort study), Diabetology & Metabolic Syndrome, 10.1186/s13098-021-00737-1, 13:1, Online publication date: 1-Dec-2021. Lee H, Lee J, Kim B, Park J, Kim D, Ahn S and Kim S (2021) Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years, Journal of Diabetes and its Complications, 10.1016/j.jdiacomp.2020.107747, 35:1, (107747), Online publication date: 1-Jan-2021. Gharibi V, Khanjani N, Khosravi A, Hossein Abadi M, Norouzi P and Khammarnia M The prevalence of metabolic syndrome among Iranian bakers, Work, 10.3233/WOR-193065, 65:1, (127-135) Wang H, Lee D, Liu M, Portincasa P and Wang D (2020) Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome, Pediatric Gastroenterology, Hepatology & Nutrition, 10.5223/pghn.2020.23.3.189, 23:3, (189), . Garg M and Mohale S (2020) Prevalence of Metabolic Obesity Normal Weight (MONW) in Cardiovascular Disease Patients - A Hospital-Based Case Control Study, Journal of Evolution of Medical and Dental Sciences, 10.14260/jemds/2020/528, 9:34, (2427-2431), Online publication date: 24-Aug-2020. Isaacson R, Beier J, Khoo N, Freeman B, Freyberg Z and Arteel G (2020) Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane, The Journal of Nutritional Biochemistry, 10.1016/j.jnutbio.2020.108399, 81, (108399), Online publication date: 1-Jul-2020. Fan L, Hao Z, Gao L, Qi M, Feng S and Zhou G (2020) Non-linear relationship between sleep duration and metabolic syndrome, Medicine, 10.1097/MD.0000000000018753, 99:2, (e18753) Xu T, Zhu G and Han S (2020) Prevalence of and lifestyle factors associated with metabolic syndrome determined using multi-level models in Chinese adults from a cross-sectional survey, Medicine, 10.1097/MD.0000000000022883, 99:44, (e22883) Woldu M, Minzi O and Engidawork E (2020) Prevalence of cardiometabolic syndrome in HIV-infected persons: a systematic review, Journal of Diabetes & Metabolic Disorders, 10.1007/s40200-020-00552-x, 19:2, (1671-1683), Online publication date: 1-Dec-2020. Di Ciaula A, Garruti G, Frühbeck G, De Angelis M, de Bari O, Wang D, Lammert F and Portincasa P The Role of Diet in the Pathogenesis of Cholesterol Gallstones, Current Medicinal Chemistry, 10.2174/0929867324666170530080636, 26:19, (3620-3638) Rashid B, Dev S, Esterman M, Schwarz N, Ferland T, Fortenbaugh F, Milberg W, McGlinchey R, Salat D and Leritz E (2019) Aberrant patterns of default‐mode network functional connectivity associated with metabolic syndrome: A resting‐state study, Brain and Behavior, 10.1002/brb3.1333, 9:12, Online publication date: 1-Dec-2019. Tegelberg P, Tervonen T, Knuuttila M, Jokelainen J, Keinänen‐Kiukaanniemi S, Auvinen J and Ylöstalo P (2019) Long‐term metabolic syndrome is associated with periodontal pockets and alveolar bone loss, Journal of Clinical Periodontology, 10.1111/jcpe.13154, 46:8, (799-808), Online publication date: 1-Aug-2019. Vekić J, Jelić-Ivanović Z, Zeljković A, Stefanović A and Spasojević-Kalimanovska V (2019) Obstructive sleep apnea and cardiometabolic risk, Arhiv za farmaciju, 10.5937/arhfarm1903153V, 69:4, (153-164), . Lu Y, Lin Y, Yen A and Chan W (2019) Dual-energy X-ray absorptiometry-assessed adipose tissues in metabolically unhealthy normal weight Asians, Scientific Reports, 10.1038/s41598-019-53557-9, 9:1, Online publication date: 1-Dec-2019. Ullrich A, Voigt L, Baumann S, Weymar F, John U, Dörr M and Ulbricht S (2018) A cross-sectional analysis of the associations between leisure-time sedentary behaviors and clustered cardiometabolic risk, BMC Public Health, 10.1186/s12889-018-5213-3, 18:1, Online publication date: 1-Dec-2018. Tinkov A, Bjørklund G, Skalny A, Holmgren A, Skalnaya M, Chirumbolo S and Aaseth J (2018) The role of the thioredoxin/thioredoxin reductase system in the metabolic syndrome: towards a possible prognostic marker?, Cellular and Molecular Life Sciences, 10.1007/s00018-018-2745-8, 75:9, (1567-1586), Online publication date: 1-May-2018. Di Ciaula A and Portincasa P (2018) Recent advances in understanding and managing cholesterol gallstones, F1000Research, 10.12688/f1000research.15505.1, 7, (1529) Shen H, Lu J, Shi T, Cheng C, Liu J, Feng J and Yang J (2018) Correlation between normal range of serum alanine aminotransferase level and metabolic syndrome, Medicine, 10.1097/MD.0000000000012767, 97:41, (e12767), Online publication date: 1-Oct-2018. Schwarz N, Nordstrom L, Pagen L, Palombo D, Salat D, Milberg W, McGlinchey R and Leritz E (2018) Differential associations of metabolic risk factors on cortical thickness in metabolic syndrome, NeuroImage: Clinical, 10.1016/j.nicl.2017.09.022, 17, (98-108), . Bjørklund G, Dadar M, Chirumbolo S and Aaseth J (2018) Fibromyalgia and nutrition: Therapeutic possibilities?, Biomedicine & Pharmacotherapy, 10.1016/j.biopha.2018.04.056, 103, (531-538), Online publication date: 1-Jul-2018. Di Ciaula A, Garruti G, Wang D and Portincasa P (2018) Cholecystectomy and risk of metabolic syndrome, European Journal of Internal Medicine, 10.1016/j.ejim.2018.04.019, 53, (3-11), Online publication date: 1-Jul-2018. Xu T, Liu J, Liu J, Zhu G and Han S (2017) Relation between metabolic syndrome and body compositions among Chinese adolescents and adults from a large-scale population survey, BMC Public Health, 10.1186/s12889-017-4238-3, 17:1, Online publication date: 1-Dec-2017. Ebrahimi E, Kheirouri S and Alizadeh M (2017) Down-regulation of S100A1 protein in patients with metabolic syndrome and its association with zinc-α2-glycoprotein, Scottish Medical Journal, 10.1177/0036933017727433, 62:3, (88-95), Online publication date: 1-Aug-2017. Campos-Nonato I, Hernandez L and Barquera S (2017) Effect of a High-Protein Diet versus Standard-Protein Diet on Weight Loss and Biomarkers of Metabolic Syndrome: A Randomized Clinical Trial, Obesity Facts, 10.1159/000471485, 10:3, (238-251), . Argote A, Mora-Hernández O, Milena Aponte L, Barrera-Chaparro D, Muñoz-Ruiz L, Giraldo-Mordecay L and Camargo D (2017) Cardiovascular Risk Factors and Carotid Intima-Media Thickness in a Colombian Population With Psoriasis, Actas Dermo-Sifiliográficas (English Edition), 10.1016/j.adengl.2017.04.006, 108:8, (738-745), Online publication date: 1-Oct-2017. Shin N, Choi J, Cho I and Park B (2017) Self-Management Program for Heart Healthy Behavior Among Middle- and Old-Aged Korean Women at Risk for Metabolic Syndrome, Journal of Cardiovascular Nursing, 10.1097/JCN.0000000000000406, 32:6, (E8-E16), Online publication date: 1-Nov-2017. Banawan L, Daabis R, Elsheikh W, Tolba M and Youssef A (2017) The prevalence of Helicobacter Pylori infection in patients with obstructive sleep apnea having metabolic syndrome and its relation to both disorders, Egyptian Journal of Bronchology, 10.4103/ejb.ejb_54_16, 11:3, (268-275), Online publication date: 1-Sep-2017. Argote A, Mora-Hernández O, Milena Aponte L, Barrera-Chaparro D, Muñoz-Ruiz L, Giraldo-Mordecay L and Camargo D (2017) Factores de riesgo cardiovascular y grosor de la íntima media carotídea en una población colombiana con psoriasis, Actas Dermo-Sifiliográficas, 10.1016/j.ad.2017.04.015, 108:8, (738-745), Online publication date: 1-Oct-2017. Marlatt K, Farbakhsh K, Dengel D and Lytle L (2016) Breakfast and fast food consumption are associated with selected biomarkers in adolescents, Preventive Medicine Reports, 10.1016/j.pmedr.2015.11.014, 3, (49-52), Online publication date: 1-Jun-2016. Shin N, Yoon J, Choi J, Park Y and Jeon S (2016) A Pilot Study of APN-led Self-management Program to Improve Cardiovascular Health Status among Korean Women with Risk Factors, Korean Journal of Adult Nursing, 10.7475/kjan.2016.28.2.237, 28:2, (237), . Lee J, Park H, Lee J, Mok B, Lee H, Lee S and Kim D (2016) Quercetin intake, MATE1 polymorphism, and metabolic syndrome in Korean population: Hallym aging study, Food Science and Biotechnology, 10.1007/s10068-016-0271-8, 25:6, (1783-1788), Online publication date: 1-Dec-2016. Iwasaki M, Minagawa K, Sato M, Kaneko N, Imai S, Yoshihara A and Miyazaki H (2014) Serum antibody to Porphyromonas gingivalis in metabolic syndrome among an older Japanese population , Gerodontology, 10.1111/ger.12135, 33:2, (193-200), Online publication date: 1-Jun-2016. Lee S, Ko Y, Kwak C and Yim E (2016) Gender differences in metabolic syndrome components among the Korean 66-year-old population with metabolic syndrome, BMC Geriatrics, 10.1186/s12877-016-0202-9, 16:1, Online publication date: 1-Dec-2016. Soreca I, Wallace M, Hall M, Hasler B, Frank E and Kupfer D (2016) The association between meal timing and frequency with cardiometabolic profile in patients with bipolar disorder, Acta Psychiatrica Scandinavica, 10.1111/acps.12578, 133:6, (453-458), Online publication date: 1-Jun-2016. Reilly C, Esiashvili N, Parashar S and Higgins M (2016) Subclinical Cardiovascular Disease in Lymphoma Survivors by Sex, Journal of Obstetric, Gynecologic & Neonatal Nursing, 10.1016/j.jogn.2015.12.014, 45:3, (438-453), Online publication date: 1-May-2016. Rizzo M, Rizvi A, Patti A, Nikolic D, Giglio R, Castellino G, Li Volti G, Caprio M, Montalto G, Provenzano V, Genovese S and Ceriello A (2016) Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study, Cardiovascular Diabetology, 10.1186/s12933-016-0480-8, 15:1, Online publication date: 1-Dec-2016. Sugiura M, Nakamura M, Ogawa K, Ikoma Y and Yano M (2015) High serum carotenoids associated with lower risk for the metabolic syndrome and its components among Japanese subjects: Mikkabi cohort study, British Journal of Nutrition, 10.1017/S0007114515003268, 114:10, (1674-1682), Online publication date: 28-Nov-2015. Rodríguez-Rodríguez S, Ruy-Díaz-Reynoso S and Vázquez-López R (2015) Tuberculosis concomitant with diabetes, Revista Médica Del Hospital General De México, 10.1016/j.hgmx.2015.06.004, 78:4, (183-187), Online publication date: 1-Oct-2015. Portincasa P and Wang D (2015) Gallstones Yamada' s Textbook of Gastroenterology, 10.1002/9781118512074.ch89, (1808-1834) Minagawa K, Iwasaki M, Ogawa H, Yoshihara A and Miyazaki H (2014) Relationship between metabolic syndrome and periodontitis in 80-year-old Japanese subjects, Journal of Periodontal Research, 10.1111/jre.12190, 50:2, (173-179), Online publication date: 1-Apr-2015. Alexanderson-Rosas E, Cruz-Mendoza J, Guinto-Nishimura G, Guízar-Sánchez C, Hernández-Sandoval S, Barrero-Mier A, De La Fuente-Mancera J, Oropeza-Aguilar M, Canales-Albarrán S, González-Padilla C, Monroy-González A, Martínez-Tapia R and Meave-González A (2015) An Increasing Mexican Population with Metabolic Syndrome-Emerging Role of Hybrid SPECT/CT and PET/CT in Cardiovascular Disease Detection, Current Cardiovascular Imaging Reports, 10.1007/s12410-015-9348-7, 8:9, Online publication date: 1-Sep-2015. Strand M, Will T, Gu X and Perry J (2015) A Descriptive Study of the Progression of the Metabolic Syndrome in Middle-Aged Chinese Population, International Quarterly of Community Health Education, 10.1177/0272684X15569490, 35:2, (163-176), Online publication date: 1-Jan-2015. Shen H, Hsu C and Tung T (2015) Economic and medical benefits of ultrasound screenings for gallstone disease, World Journal of Gastroenterology, 10.3748/wjg.v21.i11.3337, 21:11, (3337-3343), Online publication date: 21-Mar-2015. Kapravelou G, Martínez R, Andrade A, Nebot E, Camiletti-Moirón D, Aparicio V, Lopez-Jurado M, Aranda P, Arrebola F, Fernandez-Segura E, Bermano G, Goua M, Galisteo M and Porres J (2015) Aerobic interval exercise improves parameters of nonalcoholic fatty liver disease (NAFLD) and other alterations of metabolic syndrome in obese Zucker rats, Applied Physiology, Nutrition, and Metabolism, 10.1139/apnm-2015-0141, 40:12, (1242-1252), Online publication date: 1-Dec-2015. Garlichs C (2015) Epidemiology of Coronary Heart Disease in the Elderly Interventional Cardiology in the Elderly, 10.1007/978-3-319-21142-8_1, (1-12), . Winning L and Linden G (2015) Periodontitis and systemic disease, BDJ Team, 10.1038/bdjteam.2015.163, 2:10, Online publication date: 1-Nov-2015. Patti A, Al-Rasadi K, Katsiki N, Banerjee Y, Nikolic D, Vanella L, Giglio R, Giannone V, Montalto G and Rizzo M (2015) Effect of a Natural Supplement Containing Curcuma Longa , Guggul, and Chlorogenic Acid in Patients With Metabolic Syndrome , Angiology, 10.1177/0003319714568792, 66:9, (856-861), Online publication date: 1-Oct-2015. Iwasaki M, Sato M, Minagawa K, Manz M, Yoshihara A and Miyazaki H (2015) Longitudinal Relationship Between Metabolic Syndrome and Periodontal Disease Among Japanese Adults Aged ≥70 Years: The Niigata Study, Journal of Periodontology, 10.1902/jop.2015.140398, 86:4, (491-498), Online publication date: 1-Apr-2015. Kim S (2014) Sex Differences in the Association of Habitual Snoring with Metabolic Syndrome, The Journal of the Korea Contents Association, 10.5392/JKCA.2014.14.01.326, 14:1, (326-336), Online publication date: 28-Jan-2014. Jantarapakde J, Phanuphak N, Chaturawit C, Pengnonyang S, Mathajittiphan P, Takamtha P, Dungjun N, Pinyakorn S, Pima W, Prasithsirikul W and Phanuphak P (2014) Prevalence of Metabolic Syndrome Among Antiretroviral-Naive and Antiretroviral-Experienced HIV-1 Infected Thai Adults, AIDS Patient Care and STDs, 10.1089/apc.2013.0294, 28:7, (331-340), Online publication date: 1-Jul-2014. Nakanishi K, Nishida M, Ohama T, Moriyama T and Yamauchi-Takihara K (2014) Smoking Associates With Visceral Fat Accumulation Especially in Women, Circulation Journal, 10.1253/circj.CJ-13-1134, 78:5, (1259-1263), . Tilakaratne A and Soory M Anti-inflammatory Actions of Adjunctive Tetracyclines and Other Agents in Periodontitis and Associated Comorbidities, The Open Dentistry Journal, 10.2174/1874210601408010109, 8:1, (109-124) Marlatt K and Steinberger J (2014) Metabolic Syndrome: A Construct with Limited Relevance to Children, Current Cardiovascular Risk Reports, 10.1007/s12170-014-0402-9, 8:10, Online publication date: 1-Oct-2014. Pacifico L, Bonci E, Ferraro F, Andreoli G, Bascetta S and Chiesa C (2013) Hepatic Steatosis and Thyroid Function Tests in Overweight and Obese Children, International Journal of Endocrinology, 10.1155/2013/381014, 2013, (1-8), . Linden G, Lyons A and Scannapieco F (2013) Periodontal systemic associations: review of the evidence, Journal of Periodontology, 10.1902/jop.2013.1340010, 84:4-s, (S8-S19), Online publication date: 1-Apr-2013. Yan X, Barnholtz-Sloan J, Chu X, Li L, Colonie R, Webster J, Smelser D, Patel N, Prichard J and Stark A (2013) Adiposity, inflammation, genetic variants and risk of post-menopausal breast cancer findings from a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design approach, SpringerPlus, 10.1186/2193-1801-2-638, 2:1, Online publication date: 1-Dec-2013. Cooper J, Fried L, Tepper P, Barinas-Mitchell E, Conroy M, Evans R, Mori Brooks M, Woodard G and Sutton-Tyrrell K (2013) Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults, Hy